Jaroslav Hájek

机构：Samsung Medical Center, University Hospital Ostrava

发表论文 93 篇 · 总被引 5097 次 · h-index 28

代表论文

• Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma (2021 · New England Journal of Medicine · 被引 766)
• Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma (2024 · New England Journal of Medicine · 被引 311)
• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2022 · The Lancet Oncology · 被引 285)
• Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial (2021 · Circulation · 被引 149)
• Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer (2022 · JAMA Oncology · 被引 93)
• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study. (2021 · Journal of Clinical Oncology · 被引 38)